-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s 200ml Ciprofloxacin Lactate Sodium Injection has been approved.
Category:
Time：2023-01-05
At the start of the new year, Shijiazhuang No.4 Pharmaceutical Group received exciting news from its research and development efforts: its 200ml ciprofloxacin lactate sodium injection—containing 0.4g of ciprofloxacin lactate (calculated as C17H18FN3O3) and 1.8g of sodium chloride—has been approved by the National Medical Products Administration and is considered to have passed the evaluation of consistency in quality and efficacy for generic drugs. This specification is the second nationwide to receive approval.
At the start of the new year, Shijiazhuang Sihua Pharmaceutical Group’s R&D department has delivered good news: they have developed a 200ml ciprofloxacin lactate sodium injection—containing 0.4g of ciprofloxacin lactate (calculated as... C 17 H 18 FN 3 O 3 Count) and 1.8g of sodium chloride – obtained Approved by the National Medical Products Administration and treated as having passed the evaluation of consistency in quality and efficacy for generic drugs, this specification is the second to be approved nationwide.
It is understood that ciprofloxacin lactate sodium injection belongs to the class of fluoroquinolone antibiotics and is used to treat systemic infections such as urinary and genital tract infections, respiratory tract infections, gastrointestinal infections, typhoid fever, bone and joint infections, skin and soft tissue infections, and sepsis caused by susceptible bacteria.
Previously, the company developed a 100 ml ciprofloxacin lactate sodium injection—containing 0.2 g of ciprofloxacin lactate (calculated as... C 17 H 18 FN 3 O 3 The 200ml ciprofloxacin lactate sodium injection, which has been approved this time, is another specification added by the company on the basis of the previously approved 100ml ciprofloxacin lactate sodium injection. This new specification represents the company’s first nationwide approval in 2021 for a generic drug that has undergone evaluation of quality and therapeutic equivalence. The 0.9g sodium chloride specification was the first to pass such an evaluation nationwide in 2021. This approval further enhances the product line of this pharmaceutical category.
Currently, Shijiazhuang Fourth Pharmaceutical has achieved consistency in 32 varieties and 43 specifications of products, laying a solid foundation for optimizing its product portfolio and participating in market competition.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license